STAT August 6, 2024
Lizzy Lawrence

Retirements from the Food and Drug Administration are hardly shocking, especially in the wake of pandemic burnout. But when longtime medical device director Jeff Shuren announced his departure in July, the device world was stunned. Industry leaders, patient advocates, and FDA colleagues alike had grown accustomed to the ambitious, politically-savvy regulator.

“It’s sort of hard to imagine the FDA without him,” said Yale cardiologist and health...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: FDA, Govt Agencies, Medical Devices
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments
This Bill Could Make It Legal for AI to Prescribe Medicine
STAT+: Trump’s FDA navigates layoffs, exits, and a new hire

Share This Article